LOS ALTOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for […]
Expects to deliver record revenue and adjusted EBITDA for 2023, consistent with annual guidance Successfully secured Saskatchewan Registries extension to […]